Comparative Pharmacology
Head-to-head clinical analysis: FLUORODOPA F18 versus GALLIUM CITRATE GA 67.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORODOPA F18 versus GALLIUM CITRATE GA 67.
FLUORODOPA F18 vs GALLIUM CITRATE GA 67
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorodopa F18 is a radioactive diagnostic agent that is taken up by dopaminergic neurons in the striatum and converted by aromatic L-amino acid decarboxylase to fluorodopamine, which is stored in presynaptic vesicles. The emitted positrons allow for PET imaging to assess functional integrity of the nigrostriatal dopaminergic system.
Gallium citrate Ga 67 is a radiopharmaceutical that localizes in tumors and inflammatory lesions. The mechanism is not fully understood but may involve binding to transferrin and uptake via transferrin receptors, as well as accumulation in lysosomes of macrophages and tumor cells.
185-370 MBq (5-10 mCi) intravenous bolus injection for positron emission tomography imaging. Administered once per imaging session.
2-5 mCi (74-185 MBq) intravenously once; repeat imaging may require an additional 2-5 mCi at 48-72 hours.
None Documented
None Documented
110 minutes (physical half-life of F-18); biological half-life is approximately 2-3 hours, allowing imaging up to 4-6 hours post-injection.
Terminal elimination half-life: approximately 25 days (range 6-72 days) in soft tissues; reflects slow clearance from binding sites (e.g., transferrin, lactoferrin).
Primarily renal excretion; approximately 70-80% of the injected dose is excreted unchanged in urine within 2 hours, with the remainder eliminated via biliary/fecal routes (<5%).
Renal: approximately 25% within first 24 hours; fecal: approximately 10% within 48 hours; retained in tissues (bone, liver, spleen) with slow release over weeks.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical